Threshold jumps on Merck KGaA cancer deal

Threshold Pharmaceuticals Inc. (NASDAQ:THLD) gained $1.70 (132%) to $2.99 on Friday after partnering with Merck KGaA (Xetra:MRK) to co-develop and commercialize Threshold's cancer product TH-302. The product, a hypoxia-activated cytotoxic 2-nitroimidazole prodrug of the DNA alkylator bromoisophosphoramide mustard (Br-IPM), is in Phase III testing to treat soft tissue sarcoma (STS) and Phase II testing for advanced pancreatic cancer. ...